Sarepta just downgraded at Citi, here’s why

Citi downgraded Sarepta Therapeutics to Neutral from Buy with a price target of $176, up from $172. After the 30% rally post-FDA approval and label expansion of Elevidys, Sarepta is now appropriately valued, the analyst tells investors in a research note. While some sell-siders have argued for valuations of $200-plus per share, Citi’s modeling suggests a fair value of no greater than $180, the firm points out. It believes the shares “could grind higher on incremental positive news,” but sees a lack of material near-term catalysts until readout of Phase 3 ENVISION study in non-ambulatory in 2026.